目的：探讨前列腺素类药物在青光眼治疗中的疗效与经济性，为临床用药提供参考。方法：回顾性选择青光眼患者790

例，按所用药物方案不同分为拉坦前列素组62 例、曲伏前列素组356 例、贝美前列素组372 例，分别采用对应药物进行治疗，计算3

组方案的临床总有效率，并运用最小成本法进行药物经济学评价。结果：拉坦前列素组、曲伏前列素组、贝美前列素组患者的总有

效率分别为87.10％、84.27％、76.08％，差异无统计学意义（P＞0.05）；成本分别为208.00、225.00、173.00 元，贝美前列素组的成本

最低。敏感度分析结果与最小成本分析结果一致。结论：针对青光眼的治疗，贝美前列素较拉坦前列素和曲伏前列素更经济。

OBJECTIVE：To investigate the curative effect and economics of prostaglandins drugs in the treatment of glaucoma，

and to provide reference for clinical medication. METHODS：In retrospective study，a total of 790 glaucoma patients were divided

into latanoprost group（62 cases），travoprost group（356 cases）and bimatoprost group（372 cases）according to therapy regimen.

They were given relevant medicine. Total effective rate of 3 groups were calculated，and the cost-minimization method was

used for pharmacoeconomics evaluation. RESULTS：The total effective rate of 3 groups were 87.10％，84.27％，76.08％ respectively，

without statistical significance（P＞0.05）. The cost of them were 208.00 yuan，225.00 yuan and 173.00 yuan，and that of bimatoprost

group was the lowest. The results of sensitivity analysis was in line with that of cost-minimization analysis. CONCLUSIONS：

For glaucoma，bimatoprost is more economical than latanoprost and travoprost.